Artificial intelligence-driven Exscientia Ltd. has signed on a “who’s who” list of biopharma partners over the years, but on 7 January announced a $100m up front, and potentially multi-billion-dollar downstream, extension of its work with Sanofi to apply its precision medicine platform using both AI and patient tissue samples to pursue 15 novel therapies in oncology and immunology.
The new agreement, which builds on the companies’ existing 2016 deal, is just the latest tie-up with big pharma for Exscientia and is part of an accelerating trend of big pharma companies partnering with AI and machine learning-specialty firms for drug discovery and development. For example, Amgen, Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?